Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Finished Goods (2022 - 2025)

Arcutis Biotherapeutics (ARQT) has 4 years of Finished Goods data on record, last reported at $12.6 million in Q4 2025.

  • For Q4 2025, Finished Goods rose 30.2% year-over-year to $12.6 million; the TTM value through Dec 2025 reached $12.6 million, up 30.2%, while the annual FY2025 figure was $12.6 million, 30.2% up from the prior year.
  • Finished Goods reached $12.6 million in Q4 2025 per ARQT's latest filing, up from $11.6 million in the prior quarter.
  • Across five years, Finished Goods topped out at $12.6 million in Q4 2025 and bottomed at $698000.0 in Q3 2022.
  • Average Finished Goods over 4 years is $5.5 million, with a median of $4.3 million recorded in 2024.
  • Peak YoY movement for Finished Goods: surged 257.51% in 2024, then soared 30.2% in 2025.
  • A 4-year view of Finished Goods shows it stood at $1.5 million in 2022, then surged by 84.73% to $2.7 million in 2023, then soared by 257.51% to $9.6 million in 2024, then surged by 30.2% to $12.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Finished Goods were $12.6 million in Q4 2025, $11.6 million in Q3 2025, and $7.9 million in Q2 2025.